ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MTAU9937A (RO7105705) in Patients With Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03828747
Recruitment Status : Recruiting
First Posted : February 4, 2019
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A (RO7105705) in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: MTAU9937A (RO7105705) Drug: Placebo Drug: [18F]GTP1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease
Estimated Study Start Date : February 28, 2019
Estimated Primary Completion Date : September 24, 2021
Estimated Study Completion Date : September 24, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MTAU9937A (RO7105705)
MTAU9937A (RO7105705) will be administered intravenously in the double-blind treatment period, and MTAU9937A (RO7105705) will be administered in the optional open-label extension period.
Drug: MTAU9937A (RO7105705)
Participants will receive MTAU9937A (RO7105705) every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. MTAU9937A (RO7105705) will be administered Q4W in the OLE period.

Drug: [18F]GTP1
[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.

Placebo Comparator: Placebo
Placebo will be administered intravenously in the double-blind treatment period.
Drug: Placebo
Participants will placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.

Drug: [18F]GTP1
[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.




Primary Outcome Measures :
  1. Change from baseline to Week 49 in cognitive function as measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-item version (ADAS-Cog11) [ Time Frame: Baseline to Week 49 ]
    A 70-point scale used to quantify the areas of cognitive function most often affected in Alzheimer's disease. Lower scores indicate better cognitive function.

  2. Change from baseline to Week 49 in functional capacities as measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL) [ Time Frame: Baseline to Week 49 ]
    A scale used to quantify performance of activities of daily living. Scores on the ADCS-ADL range from 0-78, with higher scores indicating better ADL function.


Secondary Outcome Measures :
  1. Change from baseline to Week 49 on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [ Time Frame: Baseline to Week 49 ]
    A scale used to quantify the severity of symptoms of dementia. The CDR-SB is obtained through interviews of patients and informants, and disease severity is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The CDR-SOB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18, with the higher values representing more severe impairment.

  2. Change from baseline to Week 49 on the Mini-Mental State Examination (MMSE) [ Time Frame: Baseline to Week 49 ]
    The Mini Mental State Examination (MMSE) is a brief clinical cognitive examination commonly used to screen for dementia and other cognitive deficits that has a total score of 0-30. Higher scores indicate better cognitive function.

  3. Percentage of Participants with Adverse Events [ Time Frame: Up to approximately 51 months ]
  4. Serum concentration of MTAU9937A (RO7105705) at specified timepoints [ Time Frame: Weeks 1, 3, 5, 9, 13, 25, 37, and 49, and at treatment discontinuation (up to week 48) ]
  5. Incidence of anti-drug antibodies (ADAs) during the study relative to the prevalence of ADAs at baseline [ Time Frame: Weeks 1, 13, 25, 37 and 49, and at treatment discontinuation (up to week 48) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • National Institute on Aging/Alzheimer's Association core clinical criteria for probable AD dementia
  • Evidence of the AD pathological process, by a positive amyloid assessment either on CSF Aβ1-42 as measured on Elecsys β-Amyloid(1-42) Test System OR amyloid PET scan
  • AD dementia of moderate severity, as defined by a screening MMSE score of 16-21 points, inclusive, and a CDR-GS of 1 or 2
  • Availability of a person with sufficient contact with the participant to be able to provide accurate information on the participant's cognitive, behavioral and functional ability

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Inability to tolerate MRI procedures or contraindication to MRI
  • Contraindication to PET imaging
  • Residence in a skilled nursing facility
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or bias the assessment of the clinical or mental status of the participant to a significant degree
  • Any evidence of a condition other than AD that may affect cognition
  • Substance abuse within the past 2 years
  • Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater, or any passive immunotherapy against tau
  • Use of any passive immunotherapy (immunoglobulin) against Aβ, unless the last dose was at least 1 year prior to screening or any active immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline
  • Any other biologic therapy or previous treatment with medications specifically intended to treat Parkinsonian symptoms or any other non-AD neurodegenerative disorder within 1 year of screening
  • Systemic immunosuppressive therapy within 12 months of screening through the entire study period
  • Typical antipsychotic or neuroleptic medication within 6 months of screening
  • Daily treatment with any of the following classes of medication (except for intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting antihistamine or anticholinergic activity
  • Stimulant medications, unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03828747


Contacts
Contact: Reference Study ID Number: GN40040 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

Locations
United States, Florida
JEM Research LLC Recruiting
Atlantis, Florida, United States, 33462
Brain Matters Research, Inc. Recruiting
Delray Beach, Florida, United States, 33445
Neuropsychiatric Research; Center of Southwest Florida Recruiting
Fort Myers, Florida, United States, 33912
Compass Research East, LLC Recruiting
Orlando, Florida, United States, 32806
United States, Illinois
Alexian Brothers Neuroscience Institute Not yet recruiting
Elk Grove Village, Illinois, United States, 60007
United States, Massachusetts
Alzheimers Disease Center Recruiting
Quincy, Massachusetts, United States, 02169
United States, Pennsylvania
Abington Neurological Associates Recruiting
Willow Grove, Pennsylvania, United States, 19090
Sponsors and Collaborators
Genentech, Inc.
Investigators
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT03828747     History of Changes
Other Study ID Numbers: GN40040
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders